{"id":471131,"date":"2021-04-05T16:32:03","date_gmt":"2021-04-05T20:32:03","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=471131"},"modified":"2021-04-05T16:32:03","modified_gmt":"2021-04-05T20:32:03","slug":"cytodyn-reschedules-webcast-from-april-6-to-april-7","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/","title":{"rendered":"CytoDyn Reschedules Webcast from April 6 to April 7"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">VANCOUVER, Washington, April  05, 2021  (GLOBE NEWSWIRE) &#8212; <strong>CytoDyn Inc. (OTC.QB: CYDY)<\/strong>, (\u201cCytoDyn\u201d or the \u201cCompany&#8221;), a late-stage biotechnology company developing Vyrologix\u2122 (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman and Chief Medical Officer and Christopher Recknor, M.D., Chief Operating Officer, will host an investment community webcast which is rescheduled one day later on Wednesday, April 7, 2021.<\/p>\n<p>Management will provide a full update to its stockholders on Company activities, including recent COVID-19 initiatives and information concerning its active trials in COVID-19, NASH and cancer.<\/p>\n<p>Management will provide approximately 60 minutes to address questions submitted online by analysts and investors.<\/p>\n<p>\n        <strong>Date: <\/strong> Wednesday, April 7, 2021<br \/><strong>Time:<\/strong> 1:00 pm PT \/ 4:00 pm ET<br \/><strong>Dial-In:<\/strong> None.<br \/><strong>Questions: <\/strong><\/p>\n<ul type=\"disc\">\n<li>Prior to the webcast, questions can be submitted online to <a href=\"mailto:CYDY_Team@cytodyn.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">CYDY_Team@cytodyn.com<\/a><\/li>\n<li>During the webcast, questions can be submitted through the webcast link below.<\/li>\n<\/ul>\n<p>This is a \u201clisten only\u201d webcast, which can be accessed via CytoDyn\u2019s corporate website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x06F2Sub_b9FQl7cZ5JmEzd3Q60F58rlfQYjuGVZYq10gVg6jamUHrJk1vlsQPsVwe1BVSqbTAJ7WIXSlkSU_w==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.cytodyn.com<\/a>\u00a0under the Investors section\/IR Calendar and will be archived for 30 days. Participants are encouraged to go to the website 15 minutes prior to the start of the webcast to register, download and install any necessary software. Please note the below website will not be operational until approximately 60 minutes prior to the start of the webcast, which can be accessed via the following link:<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Sc3bnmXnl0SSG9_43DiHPtCZgzdQYcjKmW24xAFEr5Hyjybk4Mzeur-EhWSANK_yI-zSbm3nbHrND_pKI4yogOFzE0gLdpGbrqQrtXm7YjurqG5I1SY36mH39G0FbCI5R8yRxWzJRYQe881gKSiPrP1yR7m0OeFa7hG0C8-LGl4HZ_bEoJodQQNhDzWOuSyt35tba1LJO4RhytsKtW_NVG2TjDdpXaWCja-ol6bgriFCHlbNZTrbJwNHTphnCmCr3Xa1c6h-FiKAkivpo-rshw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/78449.themediaframe.com\/dataconf\/productusers\/cydy\/mediaframe\/44397\/indexl.html<\/a>\n      <\/p>\n<p>The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until May 7, 2021.<\/p>\n<p>\n        <strong>CONTACTS<\/strong><br \/>\n        <br \/>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Michael Mulholland<br \/>Office: 360.980.8524, ext. 102<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RJp7m1ONyEv9kt9-svCziPCWxsY5ykpU1amVy8DFw2yRhyY2ZDEyxa6HeiKH4i9DLW1We5GMA-WYOV7uNAQxyPO71jWQo9gvLfUjZozbOX4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mmulholland@cytodyn.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTY3NiM0MTA2Mzg0IzIwMjY1OTg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/0e7f380d-51dd-4ae2-a8c6-0a631ca5a8aa\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) &#8212; CytoDyn Inc. (OTC.QB: CYDY), (\u201cCytoDyn\u201d or the \u201cCompany&#8221;), a late-stage biotechnology company developing Vyrologix\u2122 (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman and Chief Medical Officer and Christopher Recknor, M.D., Chief Operating Officer, will host an investment community webcast which is rescheduled one day later on Wednesday, April 7, 2021. Management will provide a full update to its stockholders on Company activities, including recent COVID-19 initiatives and information concerning its active trials in COVID-19, NASH and cancer. Management will provide approximately 60 minutes to address questions submitted online by analysts and investors. Date: Wednesday, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CytoDyn Reschedules Webcast from April 6 to April 7&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-471131","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CytoDyn Reschedules Webcast from April 6 to April 7 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytoDyn Reschedules Webcast from April 6 to April 7 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) &#8212; CytoDyn Inc. (OTC.QB: CYDY), (\u201cCytoDyn\u201d or the \u201cCompany&#8221;), a late-stage biotechnology company developing Vyrologix\u2122 (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman and Chief Medical Officer and Christopher Recknor, M.D., Chief Operating Officer, will host an investment community webcast which is rescheduled one day later on Wednesday, April 7, 2021. Management will provide a full update to its stockholders on Company activities, including recent COVID-19 initiatives and information concerning its active trials in COVID-19, NASH and cancer. Management will provide approximately 60 minutes to address questions submitted online by analysts and investors. Date: Wednesday, &hellip; Continue reading &quot;CytoDyn Reschedules Webcast from April 6 to April 7&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-05T20:32:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTY3NiM0MTA2Mzg0IzIwMjY1OTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytodyn-reschedules-webcast-from-april-6-to-april-7\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytodyn-reschedules-webcast-from-april-6-to-april-7\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytoDyn Reschedules Webcast from April 6 to April 7\",\"datePublished\":\"2021-04-05T20:32:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytodyn-reschedules-webcast-from-april-6-to-april-7\\\/\"},\"wordCount\":282,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytodyn-reschedules-webcast-from-april-6-to-april-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTY3NiM0MTA2Mzg0IzIwMjY1OTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytodyn-reschedules-webcast-from-april-6-to-april-7\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytodyn-reschedules-webcast-from-april-6-to-april-7\\\/\",\"name\":\"CytoDyn Reschedules Webcast from April 6 to April 7 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytodyn-reschedules-webcast-from-april-6-to-april-7\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytodyn-reschedules-webcast-from-april-6-to-april-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTY3NiM0MTA2Mzg0IzIwMjY1OTg=\",\"datePublished\":\"2021-04-05T20:32:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytodyn-reschedules-webcast-from-april-6-to-april-7\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytodyn-reschedules-webcast-from-april-6-to-april-7\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytodyn-reschedules-webcast-from-april-6-to-april-7\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTY3NiM0MTA2Mzg0IzIwMjY1OTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMTY3NiM0MTA2Mzg0IzIwMjY1OTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytodyn-reschedules-webcast-from-april-6-to-april-7\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytoDyn Reschedules Webcast from April 6 to April 7\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytoDyn Reschedules Webcast from April 6 to April 7 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/","og_locale":"en_US","og_type":"article","og_title":"CytoDyn Reschedules Webcast from April 6 to April 7 - Market Newsdesk","og_description":"VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) &#8212; CytoDyn Inc. (OTC.QB: CYDY), (\u201cCytoDyn\u201d or the \u201cCompany&#8221;), a late-stage biotechnology company developing Vyrologix\u2122 (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman and Chief Medical Officer and Christopher Recknor, M.D., Chief Operating Officer, will host an investment community webcast which is rescheduled one day later on Wednesday, April 7, 2021. Management will provide a full update to its stockholders on Company activities, including recent COVID-19 initiatives and information concerning its active trials in COVID-19, NASH and cancer. Management will provide approximately 60 minutes to address questions submitted online by analysts and investors. Date: Wednesday, &hellip; Continue reading \"CytoDyn Reschedules Webcast from April 6 to April 7\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-05T20:32:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTY3NiM0MTA2Mzg0IzIwMjY1OTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytoDyn Reschedules Webcast from April 6 to April 7","datePublished":"2021-04-05T20:32:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/"},"wordCount":282,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTY3NiM0MTA2Mzg0IzIwMjY1OTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/","name":"CytoDyn Reschedules Webcast from April 6 to April 7 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTY3NiM0MTA2Mzg0IzIwMjY1OTg=","datePublished":"2021-04-05T20:32:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTY3NiM0MTA2Mzg0IzIwMjY1OTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMTY3NiM0MTA2Mzg0IzIwMjY1OTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytodyn-reschedules-webcast-from-april-6-to-april-7\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytoDyn Reschedules Webcast from April 6 to April 7"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=471131"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471131\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=471131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=471131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=471131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}